Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
Author:
Publisher
Informa UK Limited
Subject
Oncology
Reference128 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2. Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers
3. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
4. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
5. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Co-targeting CDK 4/6 and C-MYC/STAT3/CCND1 axis and inhibition of tumorigenesis and epithelial-mesenchymal-transition in triple negative breast cancer by Pt(II) complexes bearing NH3 as trans-co-ligand;Journal of Inorganic Biochemistry;2024-10
2. CDK4/6 inhibitors promote senescence-associated lysosomal alterations and enhance sensitivity to lysosomotropic agents in breast cancer;2024-08-23
3. Conserved role of FOXC1 in TNBC is parallel to FOXA1 in ER+ breast cancer;iScience;2024-08
4. Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer;Current Pharmaceutical Biotechnology;2024-07-31
5. Unveiling the impact: A decade review on dihydropyrimidinones (DHPMs) to combat breast cancer;Journal of Molecular Structure;2024-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3